Status:
UNKNOWN
HDL Dysfunction During the Acute Stage of Stroke
Lead Sponsor:
Centre Hospitalier Universitaire de la Réunion
Collaborating Sponsors:
Institut National de la Santé Et de la Recherche Médicale, France
Conditions:
Stroke, Acute
Eligibility:
All Genders
18+ years
Brief Summary
The study investigates the effect of plasma myeloperoxidase (MPO) concentrations on HDL dysfunction during the acute stage of ischemic and haemorrhagic strokes.
Detailed Description
MRI or CT scan are used to confirm the diagnosis of haemorrhagic, ischemic and mimick stroke. Plasma anf HDL-MPO concentrations, as well as potent HDL dysfunction, are compared in the 3 cases. The i...
Eligibility Criteria
Inclusion
- Patients with less than 12 hours stroke clinical signs:
- hemiparesis or hemiplegia
- unilateral sensitivity disorder
- language impairment
- balance disorder
- dizziness, bilateral or monocular vision totally or partially lost
Exclusion
- Pregnancy
- head trauma since the last 3 months
- stroke since the last 3 months
- myocardial infarction since the last 3 months
- patient disagrees to be enrolled in the study
Key Trial Info
Start Date :
October 20 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2020
Estimated Enrollment :
112 Patients enrolled
Trial Details
Trial ID
NCT03245957
Start Date
October 20 2017
End Date
March 1 2020
Last Update
March 7 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Reunion Island
Saint-Pierre, Reunion Island, Reunion, 97410